[{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"2e6bf495-dfa3-4ba8-b86c-4970f2d282c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01428973","created_at":"2021-01-18T05:54:04.661Z","updated_at":"2024-07-02T16:35:04.762Z","phase":"Phase 2","brief_title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","source_id_and_acronym":"NCT01428973","lead_sponsor":"University of Liege","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-09"},{"id":"9f272c5e-b3bc-4746-bc47-098aa2fc3e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05884333","created_at":"2023-06-01T14:08:00.739Z","updated_at":"2024-07-02T16:35:06.471Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Adults With Blood Cancers","source_id_and_acronym":"NCT05884333","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 05/22/2028","primary_completion_date":" 05/22/2028","study_txt":" Completion: 05/22/2028","study_completion_date":" 05/22/2028","last_update_posted":"2024-05-02"},{"id":"db2e24eb-0bfd-4e64-8863-acd072634957","acronym":"MI-Immune","url":"https://clinicaltrials.gov/study/NCT03959241","created_at":"2021-01-18T19:29:03.481Z","updated_at":"2024-07-02T16:35:11.422Z","phase":"Phase 3","brief_title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","source_id_and_acronym":"NCT03959241 - MI-Immune","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 431","initiation":"Initiation: 06/25/2019","start_date":" 06/25/2019","primary_txt":" Primary completion: 09/19/2022","primary_completion_date":" 09/19/2022","study_txt":" Completion: 09/19/2022","study_completion_date":" 09/19/2022","last_update_posted":"2024-04-04"},{"id":"8141f3b3-b073-4d91-bde0-869625884d73","acronym":"","url":"https://clinicaltrials.gov/study/NCT03480360","created_at":"2021-05-03T18:54:00.006Z","updated_at":"2024-07-02T16:35:32.843Z","phase":"Phase 3","brief_title":"Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","source_id_and_acronym":"NCT03480360","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2018","start_date":" 03/28/2018","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 09/13/2025","study_completion_date":" 09/13/2025","last_update_posted":"2023-10-18"},{"id":"fe47d81d-281e-4a03-a25c-2119fd0bd270","acronym":"","url":"https://clinicaltrials.gov/study/NCT03608059","created_at":"2021-01-18T17:44:13.474Z","updated_at":"2024-07-02T16:35:34.652Z","phase":"Phase 4","brief_title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","source_id_and_acronym":"NCT03608059","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 418","initiation":"Initiation: 07/28/2018","start_date":" 07/28/2018","primary_txt":" Primary completion: 08/23/2023","primary_completion_date":" 08/23/2023","study_txt":" Completion: 08/23/2023","study_completion_date":" 08/23/2023","last_update_posted":"2023-10-05"},{"id":"20d2383a-ae5c-429a-a889-50e462e666a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951885","created_at":"2021-01-18T08:51:05.801Z","updated_at":"2024-07-02T16:35:37.507Z","phase":"Phase 3","brief_title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","source_id_and_acronym":"NCT01951885","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 07/07/2014","start_date":" 07/07/2014","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 08/11/2021","study_completion_date":" 08/11/2021","last_update_posted":"2023-09-11"},{"id":"ed7295fd-cdd2-44a0-823e-4dae21ed1465","acronym":"","url":"https://clinicaltrials.gov/study/NCT02988466","created_at":"2021-01-18T14:42:01.766Z","updated_at":"2024-07-02T16:35:48.753Z","phase":"Phase 2","brief_title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","source_id_and_acronym":"NCT02988466","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 01/24/2017","start_date":" 01/24/2017","primary_txt":" Primary completion: 05/02/2023","primary_completion_date":" 05/02/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-05-08"},{"id":"20118668-e81b-4e8a-bc41-ef494fc1c7c2","acronym":"BMTCTN0603","url":"https://clinicaltrials.gov/study/NCT00849147","created_at":"2021-01-18T03:13:56.806Z","updated_at":"2024-07-02T16:35:58.244Z","phase":"Phase 2","brief_title":"Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)","source_id_and_acronym":"NCT00849147 - BMTCTN0603","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 06/01/2011","primary_completion_date":" 06/01/2011","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2023-01-04"},{"id":"94fe4903-a2c9-42e8-862b-770fa6d33088","acronym":"I-HEP","url":"https://clinicaltrials.gov/study/NCT04810156","created_at":"2021-03-22T11:52:24.698Z","updated_at":"2025-02-25T14:02:17.911Z","phase":"Phase 2","brief_title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","source_id_and_acronym":"NCT04810156 - I-HEP","lead_sponsor":"Inge Marie Svane","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prednisone • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/07/2025","primary_completion_date":" 04/07/2025","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2022-12-14"},{"id":"7d0269ef-d62a-464e-b888-7fb2fa28d120","acronym":"","url":"https://clinicaltrials.gov/study/NCT05250362","created_at":"2022-02-22T13:52:32.086Z","updated_at":"2024-07-02T16:36:15.354Z","phase":"Phase 1/2","brief_title":"Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT05250362","lead_sponsor":"Sichuan University","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr del(7q)","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"65b2539e-507f-4963-8ddc-bc3d35e27ae2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00350181","created_at":"2021-01-18T01:12:40.773Z","updated_at":"2024-07-02T16:36:24.074Z","phase":"Phase 2","brief_title":"Sirolimus \u0026 Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT","source_id_and_acronym":"NCT00350181","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • carmustine • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 08/01/2007","primary_completion_date":" 08/01/2007","study_txt":" Completion: 04/01/2010","study_completion_date":" 04/01/2010","last_update_posted":"2021-09-23"},{"id":"6ab1c6de-9211-4674-a4ef-ca730c3a996e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01768845","created_at":"2021-01-18T07:46:57.830Z","updated_at":"2024-07-02T16:36:29.128Z","phase":"","brief_title":"Unrelated Umbilical Cord Blood (UBC)Transplantation","source_id_and_acronym":"NCT01768845","lead_sponsor":"West Virginia University","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 02/03/2009","start_date":" 02/03/2009","primary_txt":" Primary completion: 05/14/2019","primary_completion_date":" 05/14/2019","study_txt":" Completion: 04/06/2021","study_completion_date":" 04/06/2021","last_update_posted":"2021-06-14"},{"id":"f5e017b5-0807-4ad2-82cc-1eac54c0227b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00089011","created_at":"2021-01-18T00:15:55.458Z","updated_at":"2025-02-25T16:21:49.913Z","phase":"Phase 2","brief_title":"Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00089011","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2020-01-29"},{"id":"5c4e7952-b47d-46dc-a909-0e2da191274d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00078858","created_at":"2021-01-18T00:12:55.825Z","updated_at":"2024-07-02T16:36:51.159Z","phase":"Phase 1/2","brief_title":"Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT00078858","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 01/01/2006","primary_completion_date":" 01/01/2006","study_txt":"","study_completion_date":"","last_update_posted":"2020-01-18"},{"id":"ee316b68-5754-4dd1-8c5e-d75b578589a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003145","created_at":"2021-01-17T22:50:08.801Z","updated_at":"2024-07-02T16:36:51.468Z","phase":"Phase 2","brief_title":"Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia","source_id_and_acronym":"NCT00003145","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/1997","start_date":" 08/01/1997","primary_txt":" Primary completion: 03/01/2005","primary_completion_date":" 03/01/2005","study_txt":"","study_completion_date":"","last_update_posted":"2020-01-10"},{"id":"3b89e1ad-bad0-42bd-8cab-0c2f11ac3f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01251575","created_at":"2021-01-18T05:02:38.444Z","updated_at":"2024-07-02T16:36:52.743Z","phase":"Phase 2","brief_title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","source_id_and_acronym":"NCT01251575","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 11/23/2018","primary_completion_date":" 11/23/2018","study_txt":" Completion: 02/11/2019","study_completion_date":" 02/11/2019","last_update_posted":"2019-12-09"},{"id":"378f37b1-68c6-4ce7-92eb-ec56f0b7bbb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00008177","created_at":"2021-01-17T23:54:30.611Z","updated_at":"2024-07-02T16:36:53.802Z","phase":"Phase 1","brief_title":"Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT00008177","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 07/27/1999","start_date":" 07/27/1999","primary_txt":" Primary completion: 03/21/2009","primary_completion_date":" 03/21/2009","study_txt":" Completion: 12/15/2010","study_completion_date":" 12/15/2010","last_update_posted":"2019-11-13"},{"id":"48f43301-76ea-4392-93f8-8bc868a9983f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00105001","created_at":"2021-01-18T00:20:30.652Z","updated_at":"2024-07-02T16:36:54.115Z","phase":"Phase 2","brief_title":"Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00105001","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 210","initiation":"Initiation: 11/01/2004","start_date":" 11/01/2004","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 05/08/2015","study_completion_date":" 05/08/2015","last_update_posted":"2019-10-30"},{"id":"802a4bd2-a5e8-47b3-842e-f5d71f7d018c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01634217","created_at":"2021-01-18T07:01:29.323Z","updated_at":"2024-07-02T16:37:03.684Z","phase":"Phase 1","brief_title":"Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT01634217","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 11/08/2013","start_date":" 11/08/2013","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2019-01-18"},{"id":"7778f5d4-6d5a-4b6e-8cc1-927aa852f355","acronym":"","url":"https://clinicaltrials.gov/study/NCT00112593","created_at":"2021-01-18T00:22:32.319Z","updated_at":"2025-02-25T16:21:57.663Z","phase":"","brief_title":"Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer","source_id_and_acronym":"NCT00112593","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 11/01/1999","start_date":" 11/01/1999","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":"","study_completion_date":"","last_update_posted":"2017-05-24"},{"id":"acfed0fa-a3c1-41a8-a286-295eac6ef1a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00143845","created_at":"2022-01-21T21:54:43.293Z","updated_at":"2024-07-02T16:37:24.617Z","phase":"Phase 2","brief_title":"Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant","source_id_and_acronym":"NCT00143845","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2017-03-08"},{"id":"938612a7-8ee3-4016-a251-40cb9915d48e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00763490","created_at":"2021-01-18T02:53:01.503Z","updated_at":"2024-07-02T16:37:26.902Z","phase":"Phase 2","brief_title":"Trial Of Double Umbilical Cord Blood Transplantation","source_id_and_acronym":"NCT00763490","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2016-12-23"}]